Low-Dose Aspirin for Early Pregnancy Loss Prevention
Low-dose aspirin should NOT be routinely used to prevent early pregnancy loss in women without antiphospholipid antibody syndrome (APS), as high-quality evidence shows no improvement in live birth rates for this indication.
The Evidence Against Routine Use
The available guidelines and research specifically address aspirin for preeclampsia prevention, not early pregnancy loss prevention 1. This is a critical distinction that clinicians often conflate in practice.
Recent high-quality evidence explicitly demonstrates that low-dose aspirin persists in clinical use for recurrent pregnancy loss (RPL) without APS despite no improvement in live-birth rate 2. This represents a cognitive bias problem rather than evidence-based practice—clinicians prescribe aspirin due to "action bias" (the instinct to intervene when outcomes are uncertain) rather than proven efficacy 2.
When Aspirin IS Indicated
Aspirin with heparin is effective ONLY in women with confirmed antiphospholipid syndrome who have recurrent pregnancy loss 3, 4, 5. The combination therapy reduces miscarriage rates in this specific autoimmune condition where thrombosis drives pregnancy loss 4.
Specific Indications for Aspirin in Pregnancy:
- Confirmed APS with pregnancy loss history: 60-100 mg/d aspirin + heparin 4, 5
- High risk for preeclampsia: 60-81 mg/d starting at 12-16 weeks gestation 1
- History of early-onset preeclampsia with preterm delivery <34 weeks
- Preeclampsia in >1 previous pregnancy
- Chronic hypertension, diabetes, renal disease, autoimmune disease
The Preeclampsia Evidence Does Not Apply to Early Pregnancy Loss
The USPSTF guidelines 1 demonstrate that aspirin reduces preeclampsia, preterm birth, and intrauterine growth restriction in high-risk women—but these are second and third trimester complications, not early pregnancy loss. The mechanism (anti-inflammatory effects on placental development) and timing (starting at 12+ weeks) are fundamentally different from preventing first-trimester miscarriage.
Clinical Pitfalls to Avoid
Do not extrapolate preeclampsia data to early pregnancy loss. The FDA label warns against aspirin use during pregnancy unless "definitely directed to do so by a doctor" 6, and specifically cautions about the last 3 months of pregnancy.
Do not prescribe aspirin for "unexplained" RPL without APS. While one older review 3 suggested benefit in unexplained cases, more recent systematic analysis 2 confirms this represents institutional and cognitive bias rather than evidence-based practice. The targeted use review 7 explicitly states: "In all other cases, the level of evidence of the benefit of aspirin is insufficient to recommend its routine prescription."
What to Do Instead
For women with recurrent pregnancy loss without APS:
- Complete thrombophilia workup to identify APS or other specific conditions
- If APS confirmed: aspirin + heparin combination therapy
- If no APS or thrombophilia: do not prescribe aspirin
- Provide continuity-based reassurance with scheduled follow-up and early pregnancy monitoring 2
The evidence is clear: aspirin does not improve live birth rates in early pregnancy loss without APS, and prescribing it represents action bias rather than evidence-based medicine.